Stefanie Huhn

Heidelberg University — Germany

Medicine · Health Sciences

21h-index1.5kcitations85works7.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(51), Protein Degradation and Inhibitors(17), Amyloidosis: Diagnosis, Treatment, Outcomes(14), Peptidase Inhibition and Analysis(11), Glycosylation and Glycoproteins Research(9)

Publications85 total

Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiome
Blood Advances·2026Open Access
Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy
Blood·2025Open Access
Phylogenetic reconstruction reveals early divergence and late expansion of focal lesions in multiple myeloma
Blood·2025Open Access
Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study
Blood·2025Open Access
Post-Induction Outcomes and Updated Minimal Residual Disease Analysis from GMMG-HD10/DSMM-XX (MajesTEC-5): A Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Lymphoma Myeloma & Leukemia·2025
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Nature Genetics·2025· 4 cited
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
Science Immunology·2025· 13 cited
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Journal of Clinical Oncology·2024· 49 citedOpen Access
Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
Blood·2024· 1 citedOpen Access
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
Blood·2024· 32 cited
Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial
Blood·2024Open Access
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Blood·2024· 1 cited
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
2024· 1 citedOpen Access
P-151 Dietary Oleic Acid Influences the Myeloma Immune Microenvironment and Improves Clinical Outcomes
Clinical Lymphoma Myeloma & Leukemia·2024
CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Leukemia·2024· 2 citedOpen Access
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
Blood·2024· 12 citedOpen Access
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
The Lancet Haematology·2024· 17 citedOpen Access
Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma
Amyloid·2024· 10 citedOpen Access
Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: <i>Insights from the GMMG-HD6 Clinical Trial</i>
Blood·2023Open Access
The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations
Leukemia·2023· 1 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Hartmut Goldschmidt(32), Niels Weinhold(25), Asta Försti(21), Kari Hemminki(19), Marc S. Raab(17), Katja Weisel(15), Ute Hegenbart(13), Stefan Schönland(13), Roland Fenk(12), Hans Salwender(12), Uta Bertsch(10), Mathias Hänel(10), Carsten Müller‐Tidow(10), Britta Besemer(9), Alexandra M. Poos(9), K. Elias(8), Markus Munder(8), Martin Hoffmann(8), Pavel Vodička(8), Anna Jauch(8)